Compare DexCom, Inc. (DXCM) vs Prologis Inc (PLD) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

PLD trades at $148.43, up 4.17% with bullish technical indicators and strong analyst support. The company reported Q1 2026 EPS of $1.05, beating estimates, and maintains robust fundamentals with $8.79B revenue and 41.54% net margin. Recent news highlights aggressive expansion into data centers and a rejected $16.9B bid for Segro, reflecting strategic growth initiatives.

Outlook remains positive with a $155.20 consensus price target and 57% buy ratings, though elevated P/E of 36.04 and rising debt-to-asset ratio to 37.2% pose valuation and leverage concerns. Key risks include integration challenges from acquisitions and macroeconomic sensitivity impacting industrial real estate demand.